1-苄基-1H-咪唑-2-甲醛 | 10045-65-5

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-苄基-1H-咪唑-2-甲醛
• 中文别名: 1H-2-咪唑甲醛,1-(苯基甲基)-；1-(苄基)咪唑-2-甲醛；1-(苯基甲基)-2-咪唑甲醛；2-咪唑甲醛,1-苄基-；1-苄基2-咪唑甲醛；1-苄基-2-甲酰咪唑；1-(苯基甲基)咪唑-2-甲醛
• 英文名称: N-benzylimidazole-2-carboxaldehyde
• 英文别名: 1-benzylimidazole-2-carboxaldehyde；1-benzyl-2-imidazolylcarboxaldehyde；1-Benzyl-1H-imidazole-2-carbaldehyde；1-benzylimidazole-2-carbaldehyde
• CAS: 10045-65-5
• 化学式: C₁₁H₁₀N₂O
• mdl: MFCD00088667
• 分子量: 186.213
• InChiKey: AKFHFMMKMUJLBU-UHFFFAOYSA-N

物化性质

• 沸点：
  128 °C(Press: 4 Torr)
• 密度：
  1.12±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  34.9
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933290090

反应信息

• 作为反应物：
  描述：

  1-苄基-1H-咪唑-2-甲醛 在 镍 盐酸羟胺 、 氢气 、 sodium acetate 作用下， 以 乙醇 、 水 为溶剂， 反应 4.67h， 生成 (1-苄基-1H-咪唑-2-基)甲基胺
  参考文献：
  名称：

  Some benzyl-substituted imidazoles, triazoles, tetrazoles, pyridinethiones, and structural relatives as multisubstrate inhibitors of dopamine .beta.-hydroxylase. 4. Structure-activity relationships at the copper binding site

  摘要：

  Structure-activity relationships (SAR) were determined for novel multisubstrate inhibitors of dopamine beta-hydroxylase (DBH; EC 1.14.17.1) by examining the effects upon in vitro inhibitory potencies resulting from structural changes at the copper-binding region of inhibitor. Attempts were made to determine replacement groups for the thione sulfur atom of the prototypical inhibitor 1-(4-hydroxybenzyl)imidazole-2-thione described previously. The synthesis and evaluation of oxygen and nitrogen analogues of the soft thione group demonstrated the sulfur atom to be necessary for optimal activity. An additional series of imidazole-2-thione relatives was prepared in an effort to probe the relationship between the pKa of the ligand group and inhibitory potency. In vitro inhibitory potency was shown not to correlate with ligand pKa over a range of approximately 10 pKa units, and a rationale for this is advanced. Additional ligand modifications were prepared in order to explore bulk tolerance at the enzyme oxygen binding site and to determine the effects of substituting a six-membered ligand group for the five-membered imidazole-2-thione ligand.

  DOI：

  10.1021/jm00164a051
• 作为产物：
  描述：

  溴甲苯 在 正丁基锂 、 potassium carbonate 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 1.67h， 生成 1-苄基-1H-咪唑-2-甲醛
  参考文献：
  名称：

  利用手性C1对称二氮配体的不对称铜（II）催化的硝基醛（亨利）反应

  摘要：

  通过手性胺与各种取代的咪唑甲醛的缩合，可以方便地以高收率合成一系列手性C 1对称二氮配体。配体L1与CuCl 2 · 2H 2 O结合可以高产率（高达97％）和良好的对映选择性（高达96％）有效地促进各种醛与硝基甲烷之间的硝基醛（亨利）反应。

  DOI：

  10.1002/ejoc.201100857

文献信息

• 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof
  申请人：——

  公开号：US20030229079A1

  公开（公告）日：2003-12-11

  Certain 1-(aromatic- or heteroaromatic-substituted-3-(heteroaromatic substituted)-1,3-propanediones are described as inhibitors of HIV integrase and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.

  某些1-(芳香基或杂芳基取代的3-(杂芳基取代)-1,3-丙二酮被描述为HIV整合酶的抑制剂和HIV复制的抑制剂。这些化合物在预防或治疗HIV感染以及治疗艾滋病方面是有用的，无论是作为化合物、药学上可接受的盐、药用组合成分，无论是否与其他抗病毒药物、免疫调节剂、抗生素或疫苗结合使用。还描述了治疗艾滋病的方法以及预防或治疗HIV感染的方法。
• Substituted heterocyclylisoquinolinium salts and compositions and method
  申请人：Sterling Winthrop Inc.

  公开号：US05569655A1

  公开（公告）日：1996-10-29

  Substitutued heterocyclylisoquinolinium salts, pharmaceutical compositions containing them and methods for the treatment or prevention of neurodegenerative disorders or neurotoxic injuries utilizing them.

  取代杂环异喹啉盐，含有它们的药物组合物以及利用它们治疗或预防神经退行性疾病或神经毒性损伤的方法。
• Selection of Chiral Zinc Catalysts for the Kinetic Resolution of Esters via Dynamic Templating
  作者：R. Kannappan、K. M. Nicholas

  DOI：10.1021/co3001023

  日期：2013.2.11

  of chiral tetradentate bis-imine zinc(II) complexes have been prepared and screened for (1) their discrimination of enantiomeric picolinate esters and pyridyl phosphonate transition state analogs (TSAs) and (2) their catalytic activity and selectivity for enantioselective methanolysis of racemic picolinate esters. The zinc complexes are in equilibrium with their imine ligands as well as with the aldehyde

  制备并筛选了手性四齿双亚胺锌（II）配合物的动态组合库，用于（1）鉴别对映体吡啶甲酸酯和吡啶基膦酸酯过渡态类似物（TSA），以及（2）催化活性和对映选择性甲醇分解的选择性外消旋吡啶甲酸酯。锌配合物与其亚胺配体以及形成它们的醛和胺结构单元处于平衡状态，从而使文库的组成能够适应配位底物或TSA的引入。二进制（L）的Zn（OTF）（SOLV）+络合物单独地或在由手性酒石酸盐衍生的二胺（库产生的2，3）和一组N-杂环醛（4 – 12）和通过ESI-MS分析建立的配合物分布。（diimine）Zn（OTf）2复杂文库与对映异构体R-和S -2-吡啶基膦酸酯TSA 13的结合研究表明，通过形成对映异构体比率低至中等的非对映异构体LZn（R / S - 13）+络合物形成手性区分，k R / k S（α），范围从0.5到5.0；选定的二元配合物与对映体底物PyrCO 2 CH（OH）Ph（1的相应模板），手性识别率可忽略不计。几种L
• Manganese-Catalyzed Enantioselective Hydrogenation of Simple Ketones Using an Imidazole-Based Chiral PNN Tridentate Ligand
  作者：Fei Ling、Jiachen Chen、Sanfei Nian、Huacui Hou、Xiao Yi、Feifei Wu、Min Xu、Weihui Zhong

  DOI：10.1055/s-0039-1690783

  日期：2020.2

  A series of Mn(I) catalysts containing imidazole-based chiral PNN tridentate ligands with controllable ‘side arm’ groups have been established, enabling the inexpensive base-promoted asymmetric hydrogenation of simple ketones with outstanding activities (up to 8200 TON) and good enantioselectivities (up to 88.5% ee). This protocol features wide substrate scope and functional group tolerance, thereby

  已经建立了一系列含有咪唑基手性 PNN 三齿配体和可控“侧臂”基团的 Mn(I) 催化剂，使具有出色活性（高达 8200 TON）和良好对映选择性的简单酮的廉价碱促进不对称氢化成为可能（高达 88.5% ee）。该协议具有广泛的底物范围和官能团耐受性，从而可以轻松获得克唑替尼的关键中间体。
• [EN] INDOLIZINE DERIVATIVES WITH CRTH2 RECEPTOR AFFINITY FOR THE TREATMENT OF INFLAMMATORY DISEASES<br/>[FR] DÉRIVÉS D'INDOLIZINE AVEC UNE AFFINITÉ POUR LE RÉCEPTEUR CRTH2 DESTINÉS AU TRAITEMENT DE MALADIES INFLAMMATOIRES
  申请人：ARGENTA DISCOVERY LTD

  公开号：WO2009044147A1

  公开（公告）日：2009-04-09

  Compounds of formula (I) are ligands of the CRTH2 receptor, useful in the treatment of, for example, inflammatory respiratory disease: R1 is fluoro, chloro, CN or CF3; R2 is hydrogen, fluoro or chloro; X is -CH2-, or - S(O)n-; Ar1 is phenyl or 5- or 6-membered heteroaryl, wherein the phenyl or heteroaryl rings are optionally substituted with one substituent selected from fluoro, chloro, CN, -O(C1-C3alkyi) or C1-C3alkyl, the latter two groups being optionally substituted by one or more fluoro atoms; Y is -CR3R4-, -C(O)-, -O-, -S(O)2- or -NR3-; R3 and R4 independently represent hydrogen or C1-C3alkyl; Ar2 is phenyl or 5- or 6- membered heteroaryl, wherein the phenyl or heteroaryl rings are optionally substituted by one or more substituents independently selected from halogen, - CN, -S(O)nR5, -S(O)2NR6R7, -NR6S(O)2R5 -NR6R7, -NR6COR5, -CONR6R7, -COR5, -OR6, C1- C6alkyl or C3-C7cycloalkyl, the latter two groups being optionally substituted by one or more fluoro atoms; R5 is C1-C6alkyl or C3-C7cycloalkyl, optionally substituted by one or more fluoro atoms; R6 and R7 independently represent hydrogen, C1-C6alkyl or C3-C7cycloalkyl, the latter two groups being optionally substituted by one or more fluoro atoms; and n is O, 1 or 2.

  化合物的结构式（I）是CRTH2受体的配体，在治疗例如炎症性呼吸道疾病方面很有用：R1是氟、氯、CN或CF3；R2是氢、氟或氯；X是-CH2-或-S(O)n-；Ar1是苯基或5-或6-成员杂环基，其中苯基或杂环基环可以选择性地用来自氟、氯、CN、-O（C1-C3烷基）或C1-C3烷基的一个取代基取代，后两个基可以选择性地用一个或多个氟原子取代；Y是-CR3R4-，-C(O)-，-O-，-S(O)2-或-NR3-；R3和R4独立地代表氢或C1-C3烷基；Ar2是苯基或5-或6-成员杂环基，其中苯基或杂环基环可以选择性地用一个或多个取代基独立地选自卤素、-CN、-S(O)nR5、-S(O)2NR6R7、-NR6S(O)2R5、-NR6R7、-NR6COR5、-CONR6R7、-COR5、-OR6、C1-C6烷基或C3-C7环烷基取代，后两个基可以选择性地用一个或多个氟原子取代；R5是C1-C6烷基或C3-C7环烷基，可以选择性地用一个或多个氟原子取代；R6和R7独立地代表氢、C1-C6烷基或C3-C7环烷基，后两个基可以选择性地用一个或多个氟原子取代；n是O、1或2。

表征谱图